The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 178 of the 179 references it cites were found in a registry or an index.
Abstract
Cholinergic synapses are ubiquitous in the human central nervous system. Their high density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic transmission is likely to be critically important for memory, learning, attention and other higher brain functions. Several lines of research suggest additional roles for cholinergic systems in overall brain homeostasis and plasticity. As such, the brain's cholinergic system occupies a central role in ongoing research related to normal cognition and age-related cognitive decline, including dementias such as Alzheimer's disease. The cholinergic hypothesis of Alzheimer's disease centres on the progressive loss of limbic and neocortical cholinergic innervation. Neurofibrillary degeneration in the basal forebrain is believed to be the primary cause for the dysfunction and death of forebrain cholinergic neurons, giving rise to a widespread presynaptic cholinergic denervation. Cholinesterase inhibitors increase the availability of acetylcholine at synapses in the brain and are one of the few drug therapies that have been proven clinically useful in the treatment of Alzheimer's disease dementia, thus validating the cholinergic system as an important therapeutic target in the disease. This review includes an overview of the role of the cholinergic system in cognition and an updated understanding of how cholinergic deficits in Alzheimer's disease interact with other aspects of disease pathophysiology, including plaques composed of amyloid-β proteins. This review also documents the benefits of cholinergic therapies at various stages of Alzheimer's disease and during long-term follow-up as visualized in novel imaging studies. The weight of the evidence supports the continued value of cholinergic drugs as a standard, cornerstone pharmacological approach in Alzheimer's disease, particularly as we look ahead to future combination therapies that address symptoms as well as disease progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The FDA approved two anti-amyloid immunotherapies, lecanemab and donanemab, for “early-stage” AD, encompassing both stage 3 (MCI) and stage 4 (mild dementia).”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [18]
In the citing paper
“Degeneration of cholinergic neurons is known to significantly contribute to cognitive decline in AD patients [132] and has been studied in a variety of genetic AD mouse models.”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [132]
In the citing paper
“AChE contributes to acetylcholine depletion and may facilitate the formation of neurotoxic Aβ-AChE complexes38.”
From Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses microglial inflammation in Alzheimer’s disease models (2026) · cites this paper as [38]
In the citing paper
“Cholinergic deficit also alters the permeability of the blood brain barrier causing erroneous transportation of metabolites and hampering the removal of amyloid plaque, worsening the disease condition [8].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [8]
In the citing paper
“From this point of view, AD could be prevented or effectively treated by decreasing the production of Aβ and tau; preventing aggregation or misfolding of these proteins; neutralizing or removing the toxic aggregate or misfolded forms of these proteins; or a combination of these modalities.7”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [7]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., & Perry, R. H. (1978) · BMJ · doi:10.1136/bmj.2.6150.1457 · Cited by 2,042
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Human Memory and the Cholinergic System: A Relationship to Aging?
Drachman, D. A. (1974) · Archives of Neurology · doi:10.1001/archneur.1974.00490320001001 · Cited by 1,397
NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311
Research works printed but not linked: 1
- Geula, 1994, Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease, 263
Cited by
Items 901–1,000 of 1,002
Samal, M., Srivastava, V., Khan, M., Insaf, A., Penumallu, N. R., Alam, A., Parveen, B., Ansari, S. H., & Ahmad, S. (2024) · Phytotherapy Research · doi:10.1002/ptr.8344 · Cited by 9
Mu, R.-H., Hou, X., Liu, Q., Wang, W., Qin, C., & Li, H. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111786 · Cited by 9
The NGF Metabolic Pathway: New Opportunities for Biomarker Research and Drug Target Discovery
Pentz, R., & Iulita, M. F. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-74046-7_4 · Cited by 9
Xiao, Y., Spotorno, N., An, L., Bazinet, V., Hansen, J. Y., Strandberg, O. T., Shafiei, G., Behjat, H., Funck, T., Salvadó, G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.17.648358 · Cited by 9
Foresee Novel Targets for Alzheimer’s Disease by Investigating Repurposed Drugs
Agarwal, K., Katare, D. P., & Jakhmola-Mani, R. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220622162622 · Cited by 9
Rethinking early Alzheimer’s disease: An impaired internal model updating disorder?
Antonioni, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106790 · Cited by 9
Caneus, J., Autar, K., Akanda, N., Grillo, M., Long, C. J., Jackson, M., Lindquist, S., Guo, X., Morgan, D., & Hickman, J. J. (2024) · Scientific Reports · doi:10.1038/s41598-024-73869-9 · Cited by 9
Jeevanandam, J., Tsenov, G., Danquah, M. K., Ruiz‐Molina, D., Boussios, S., & Ovsepian, S. V. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-025-00813-6 · Cited by 9
CD2AP at the junction of nephropathy and Alzheimer’s disease
Vandal, M., Janmaleki, M., Rea, I. M., Gunn, C., Hirai, S., Biernaskie, J. A., Chun, J., Gordon, G. R., Shaw, A. S., Sanati‐Nezhad, A., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00852-x · Cited by 9
Nanoparticles for the potential treatment of Alzheimer’s disease: A physiopathological approach
Martínez, N. M. N., Toledo, J. A., & Morales, J. O. (2023) · Nanotechnology Reviews · doi:10.1515/ntrev-2022-0548 · Cited by 9
Anticholinergic burden and incident dementia: a Swedish nationwide case-control study
Zhu, N., Eriksdotter, M., Liabeuf, S., Tan, E. C. K., Johnell, K., Ptacek, S. G., & Xu, H. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01883-8 · Cited by 9
Zhao, L., Cheng, X., & Zhong, C. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00450 · Cited by 9
Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions
Mohapatra, T. K., Nayak, R. R., Ganeshpurkar, A., Tiwari, P. K., & Kumar, D. (2025) · Ibrain · doi:10.1002/ibra.12197 · Cited by 9
Cholinesterase inhibitor use in amyloid PET-negative mild cognitive impairment and cognitive changes
Pyun, J., Park, Y. H., Kang, M. J., & Kim, S. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01580-y · Cited by 9
Current pharmacophore based approaches for the development of new anti-Alzheimer’s agents
Sharma, P., Sharma, S., YADAV, Y. R., Shukla, P., & Sagar, R. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117926 · Cited by 9
Exploring the therapeutic potential of steroidal alkaloids in managing Alzheimer’s disease
Pandey, P. P., & Kumar, M. S. (2024) · Steroids · doi:10.1016/j.steroids.2024.109468 · Cited by 9
Kwon, M.-J., Lee, J.-W., Kim, K., Chen, H., Cui, C., Lee, G. W., & Cho, Y. H. (2022) · Molecules · doi:10.3390/molecules27144455 · Cited by 9
Micro and nanoemulsion as drug carriers in Alzheimer's disease
Patel, A. K., Paliwal, H., Sawant, K. K., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00013-3 · Cited by 10
Pereira, M. E., Lima, L. S., Souza, J. V., da Costa, N. D. S., da Silva, J. F., Guiloski, I. C., Irioda, A. C., & Oliveira, C. S. (2023) · Biological Trace Element Research · doi:10.1007/s12011-023-03893-9 · Cited by 9
Muratori, B. G., da Veiga, I. E. T., Medeiros, G. N., da Silva, S. S., Soliani, A. G., Prado, C. M., & Cerutti, S. M. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.115455 · Cited by 9
Chauhan, P., Begum, M. Y., Narapureddy, B. R., Gupta, S., Wadhwa, K., Singh, G., Kumawat, R., Sharma, N., Ballal, S., Jha, S. K., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04535-4 · Cited by 9
Jing, L., Wei, W., Meng, B., Chantegreil, F., Nachon, F., Martínez, A., Wu, G., Zhao, H., Song, Y., Kang, D., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106465 · Cited by 9
Balkrishna, A., Bhattacharya, K., Shukla, S., & Varshney, A. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03601-7 · Cited by 9
Protein kinases as therapeutic targets for Alzheimer’s disease: a brief review
Silva, I. M. F., Franco, G. D. R. R., Gontijo, V. S., & Viegas, C. (2024) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.00092 · Cited by 9
McDonald, A. J. (2024) · Journal of Neuroscience Research · doi:10.1002/jnr.25318 · Cited by 9
Gangoda, D. M., Saiyed, M. S., Pathan, S. R., Sharma, K. B., Patel, V. A., Sachdeva, P. D., Patel, M. Y., & Patel, M. D. (2023) · Cureus · doi:10.7759/cureus.48400 · Cited by 9
Cao, N., Li, S., Xu, A., Li, M., Zou, X., Ke, Z., Deng, G., Cheng, X. M., & Wang, C. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.773638 · Cited by 9
Song, R., Chen, H., Zhan, R., Han, M., Zhao, L., & Shen, X. (2023) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2023.127326 · Cited by 9
Saeed, R., Tariq, H. Z., Althobaiti, A., Sadeghian, N., Taslımı, P., al‐Rashida, M., Islam, T., Thabet, H. K., Aftab, H., Şenol, H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-32012-y · Cited by 9
Bai, Y., Ren, D., Xue, X., Gao, W., Hu, J., & Pan, H. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.105388 · Cited by 9
Ye, Q., Nunez, J., & Zhang, X. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16115 · Cited by 9
Huang, T., Lee, S. B., Lee, T., Yun, S., Kim, Y.-D., & Yang, H. (2023) · Plants · doi:10.3390/plants12030640 · Cited by 9
Kubis-Kubiak, A., Wiatrak, B., & Piwowar, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115526 · Cited by 9
Mazej, T., Knez, D., Meden, A., Gobec, S., & Sova, M. (2021) · Molecules · doi:10.3390/molecules26144118 · Cited by 9
PET Imaging of Acetylcholinesterase
Shinotoh, H., Hirano, S., & Shimada, H. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_7 · Cited by 9
Lin, C., Li, H., & Wang, J. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae611 · Cited by 9
Baruah, P., Ray, D., Konthoujam, I., Das, A., Chakrabarty, S., Aguan, K., & Mitra, S. (2022) · New Journal of Chemistry · doi:10.1039/d2nj04365c · Cited by 9
Barbosa, D. B., do Bomfim, M. R., de Oliveira, T. A., da Silva, A. M., Taranto, A. G., Cruz, J. N., de Carvalho, P. B., Rosa, J. M. C., Santos, C. B. R., & Leite, F. H. A. (2023) · Pharmaceuticals · doi:10.3390/ph16121657 · Cited by 9
Almeida, M. P., Kock, F. V. C., de Jesus, H. C. R., Carlos, R. M., & Venâncio, T. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111560 · Cited by 9
Chen, Z., Fu, L., Liu, X.-A., Yang, Z., Li, W., Li, F., & Luo, Q. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.09.060 · Cited by 9
Li, D., Jiang, F., Zhang, H., Zheng, L., Wang, Q., Fu, R., Liu, X., & Gao, P. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14068 · Cited by 9
In silico Screening of Pyridoxine Carbamates for Anti-Alzheimer’s Activities
Baswar, D., Sharma, A., & Mishra, A. (2020) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524920666201119144535 · Cited by 9
Roberts, J. A., Varma, V. R., Jones, A., & Thambisetty, M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240680 · Cited by 8
Oxidative Stress in Neurodegenerative Diseases
Alami, M., Fülöp, T., Boumezough, K., Khalil, A., Zerif, E., & Berrougui, H. (2024) · Springer eBooks · doi:10.1007/978-3-031-69962-7_4 · Cited by 8
Koukouli, F., Zhang, C.-L., Lazarevich, I. A., Rooy, M., d’Incamps, B. L., Santos, D. G., Pons, S., Peixoto, J., Thiberge, C., Nikolakopoulou, I., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03241-4 · Cited by 8
More, S. A., Mundke, R. N., Agrawal, Y. O., Awathale, S. N., Goyal, S. N., Nakhate, K. T., & Rathod, S. S. (2026) · Laboratory Animal Research · doi:10.1186/s42826-026-00278-6 · Cited by 8
Zhao, L., Niu, L., Dai, H., Lee, T. M. C., Huang, R., & Zhang, R. (2024) · Psychological Medicine · doi:10.1017/s0033291724002563 · Cited by 8
DAT1 and BDNF polymorphisms interact to predict Aβ and tau pathology
Ciampa, C. J., Morin, T., Murphy, A., Joie, R. L., Landau, S. M., & Berry, A. S. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.10.009 · Cited by 8
Border-associated macrophages: From physiology to therapeutic targets in Alzheimer's disease
Zheng, F., Dong, T., Chen, Y., Wang, L., & Peng, G. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.115021 · Cited by 8
Kotova, M. M., Stewart, A., Grigoryan, A., Shariff, S., Mirzaei, F., Kantawala, B., Dilbaryan, K., de Abreu, M. S., Galstryan, D. S., Cui, J., et al. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70090 · Cited by 8
Jeong, G. S., Lee, E.-Y., Kang, M.-G., Nam, S., Park, D., & Kim, H. (2022) · Processes · doi:10.3390/pr10010166 · Cited by 8
Medicinal plants possessed beneficial therapeutic effects in Alzheimer’s disease and memory deficits
Al‐Snafi, A. E. (2021) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2021.17.2.0321 · Cited by 8
Altered local intrinsic neural activity and molecular architecture in internet use disorders
Ma, L., Tao, Q., Dang, J., Sun, J., Niu, X., Zhang, M., Kang, Y., Wang, W., Cheng, J., Han, S., et al. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111052 · Cited by 8
Hamza, E. A., Moustafa, A. A., Tindle, R., Karki, R., Nalla, S., Hamid, M. S., & Haj, M. E. (2022) · Current Alzheimer Research · doi:10.2174/1567205020666230309113749 · Cited by 8
Cherian, A. K., Tronson, N. C., Parikh, V., Kucinski, A. J., Blakely, R., & Sarter, M. F. (2019) · Behavioral Neuroscience · doi:10.1037/bne0000310 · Cited by 8
Phytochemical based Modulation of Endoplasmic Reticulum Stress in Alzheimer's Disease
Dsouza, V. L., Shivakumar, A. B., Kulal, N., Gangadharan, G., Kumar, D., & Kabekkodu, S. P. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220624155357 · Cited by 8
Avendaño-Godoy, J., Miranda, A., Sigrid Mennickent, C., & Gómez-Gaete, C. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.08.011 · Cited by 8
Resistance and Resilience to Alzheimer's Disease
Latimer, C. S., Prater, K. E., Postupna, N. O., & Keene, C. D. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041201 · Cited by 8
Tettevi, E. J., Simpong, D. L., Maina, M. B., Adjei, S., Asuming-Brempong, E. K., Osei-Atweneboana, M. Y., & Ocloo, A. (2025) · Brain and Behavior · doi:10.1002/brb3.70946 · Cited by 8
Li, D., Yang, H., Lyu, M., Zhou, L., Zhang, Y., Kang, C., Wang, J., & Wang, Y. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105207 · Cited by 8
Targeting the awry Aβ pathway in Alzheimer’s disease: hype and hurdles
Al-Kuraishy, H. M., Sulaiman, G. M., Al-Gareeb, A. I., Mohammed, H. A., Albuhadily, A. K., & Abomughaid, M. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01983-9 · Cited by 8
Huprines — an insight into the synthesis and biological properties
Mezeiová, E., Soukup, O., & Korábečný, J. (2020) · Russian Chemical Reviews · doi:10.1070/rcr4938 · Cited by 8
Recent advances in nanotechnology for combating Alzheimer's disease
Hu, C., Wu, B., Wu, Y., Shi, M., Ma, J., Gao, H., & Zhang, J. (2023) · Materials Chemistry Frontiers · doi:10.1039/d3qm00493g · Cited by 8
Genes related to neurotransmitter receptors as potential biomarkers for Alzheimer's disease
Chen, W., Zhang, T., & Zhang, H. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137816 · Cited by 8
Medial septal cholinergic neurotransmission is essential for social memory in mice
Shivakumar, A. B., Mehak, S. F., Gupta, A., & Gangadharan, G. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111207 · Cited by 8
Maafi, N., Pidaný, F., Maříková, J., Korábečný, J., Hulcová, D., Kučera, T., Schmidt, M., Shammari, L. A. A., Špulák, M., Catapano, M. C., et al. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128374 · Cited by 8
Zhang, Y., Silang, Q., Wang, T., Wang, N., Gesang, L., Tang, L., & Liu, L. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s537129 · Cited by 8
Şenol, F. S., Salmas, R. E., Emerce, E., Şener, B., & Orhan, İ. E. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230417083053 · Cited by 8
Naffaa, M. M., & Yin, H. H. (2024) · Science Signaling · doi:10.1126/scisignal.adk8810 · Cited by 8
Blackwell, A. A., Jodelka, F. M., Lake, R. I., Hastings, M. L., & Wallace, D. G. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.12.012 · Cited by 8
Dean, B., Haroutunian, V. H., & Scarr, E. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.03.035 · Cited by 8
Repurposing of Minocycline, a Tetracycline Antibiotic, for Neurodegenerative Disorders
Bhandari, R., Sood, P., Thakur, D., & Kuhad, A. (2023) · Springer eBooks · doi:10.1007/978-981-19-5399-6_27 · Cited by 8
Using Optogenetics to Model Cellular Effects of Alzheimer’s Disease
Tiwari, P., & Tolwinski, N. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054300 · Cited by 8
Olasehinde, T. A., & Olaniran, A. O. (2024) · Environmental Toxicology · doi:10.1002/tox.24418 · Cited by 8
miR-33-3p Regulates PC12 Cell Proliferation and Differentiation In Vitro by Targeting Slc29a1
Shan, B., Li, W., He, H., Zhao, H., Tian, M.-L., Cheng, X., Qin, J., & Jin, G. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03377-z · Cited by 8
Soares, M. S. P., Luduvico, K. P., Chaves, V. C., Spohr, L., Meine, B. D. M., Lencina, C. L., Reginatto, F. H., Spanevello, R. M., Simões, C. M. O., & Stefanello, F. M. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03248-7 · Cited by 8
Evaluation of radiolabeled acetylcholine synthesis and release in rat striatum
Muramatsu, I., Uwada, J., Chihara, K., Sada, K., Wang, M., Yazawa, T., Taniguchi, T., Ishibashi, T., & Masuoka, T. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15556 · Cited by 8
Kang, C. M., Bang, J. S., Park, S. Y., Jung, T. W., Kim, H., Chung, Y., & Jeong, J. H. (2022) · Journal of Medicinal Food · doi:10.1089/jmf.2021.k.0197 · Cited by 8
Aksöz, B. E., & Aksöz, E. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666200220115154 · Cited by 8
Çam, M. E., & Taşkın, T. (2020) · Clinical and Experimental Health Sciences · doi:10.33808/clinexphealthsci.685280 · Cited by 8
Eye Movement in Neurological Disorders
Das, J., Graham, L., Morris, R., Barry, G., Godfrey, A., Walker, R. W., & Stuart, S. (2022) · Neuromethods · doi:10.1007/978-1-0716-2391-6_11 · Cited by 8
Jeyabalan, J. B., Palathoti, N., Dhanasekaran, M., Sivasamy, R., Ponnusankar, S., Dhanabal, S. P., Sankar, V., & Justin, A. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06684-1 · Cited by 8
Gollapalli, P., Gnanasekaran, T. S., Rao, S. J. A., Manjunatha, H., Shetty, P. K., & Kumari, S. (2022) · Current Drug Discovery Technologies · doi:10.2174/1570163819666220825141356 · Cited by 8
Magalhães-Gomes, M. P. S., Camargos, W., Valadão, P. A. C., Garcias, R., Rodrigues, H. A., Andrade, J. N., Teixeira, V. P., Naves, L. A., Cavalcante, W. L. G., Gallacci, M., et al. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2020.12.025 · Cited by 8
Putluru, D. R., Tepole, A. B., & Gómez, H. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00691-4 · Cited by 8
Öztürk, Ö., Farouk, F. M., Ooi, L., Law, C. S. W., Muhammed, M. T., Aki, E., & Yeong, K. Y. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10476-8 · Cited by 8
Permana, A., Akili, A. W. R., Hardianto, A., Latip, J., Sulaeman, A. P., & Herlina, T. (2025) · Advances and Applications in Bioinformatics and Chemistry · doi:10.2147/aabc.s495947 · Cited by 8
Exploring the diagnostic markers of essential tremor: A study based on machine learning algorithms
Gao, Y., Ding, L., Liu, J., Wang, X., & Meng, Q. (2023) · Open Life Sciences · doi:10.1515/biol-2022-0622 · Cited by 8
Cheng, L., Shi, C., Nakamura, S., Esaki, N., Ichiba, Y., Tanaka, M., Sakai, K., & Matsui, T. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c07821 · Cited by 8
New and potential boron-containing compounds for treatment of Alzheimer's disease and cancers
Önder, F. C., Ural, K., Önder, A., Ozpolat, B., & Ay, M. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2525065 · Cited by 8
Zhang, R., He, X., Cheng, J., Zhang, X., Chen, H., Liu, Y., Chen, P., & Wang, Y. (2023) · Neurotoxicity Research · doi:10.1007/s12640-023-00677-w · Cited by 8
Panova, E. V., & Safin, D. A. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143359 · Cited by 8
Mohammadnezhad, P., Valdés, A., Barrientos, R. E., Ibáñez, E., Block, J. M., & Cifuentes, A. (2023) · Foods · doi:10.3390/foods12203879 · Cited by 8
Sun, Y., Xia, Q., Du, L., Gan, Y., Ren, X., Liu, G., Wang, Y., Yan, S., Li, S., Zhang, X., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116754 · Cited by 7
Ji, S.-L., Wang, W., Ma, S., Zhang, P., Xiang, Z., Liu, G., Wu, J., Wang, K., & Pan, J. (2025) · Talanta · doi:10.1016/j.talanta.2025.129169 · Cited by 7
Nicotinic acetylcholine receptors-targeting drug discovery
Zhang, D., Zheng, H., Cui, K., Li, Y., Liu, C., Mao, J., Zheng, J., & Wan, Y. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118679 · Cited by 7
Ţînţaş, M.-L., Peauger, L., Barré, A., Papamicaël, C. A., Besson, T., Santos, J. S. O., Gembus, V., & Levacher, V. (2024) · RSC Medicinal Chemistry · doi:10.1039/d3md00708a · Cited by 7
Liposomal Drug Delivery for Neurological Disorders: Advances and Challenges
Javed, A., Mandal, P., Khan, I., Singh, A. P., Akhtar, J., Maheshwari, S., & Prajapati, B. G. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249319942240903134353 · Cited by 7
Wang, L., Ji, M. J., Sun, H., Gan, C., Zhang, H., Cao, X., Yuan, Y., & Zhang, K. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223498 · Cited by 7
Wu, Y., Gao, Y., Tie, F., Wang, R., Hu, N., Dong, Q., Fu, C., & Wang, H. (2025) · Molecules · doi:10.3390/molecules30183686 · Cited by 6
Metadata
- Authors
- Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., & Khachaturian, Z. S.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Northwestern University (US)
- McGill University (CA)
- Indiana University School of Medicine (US)
- University Hospital of Geneva (CH)
- Saint Louis University (US)
- Prevent Alzheimer’s Disease 2020 (US)
- University of Rhode Island (US)
- Corresponding author
- Hampel, Harald
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-05-29
- Volume
- 141
- Issue
- 7
- Pages
- 1917-1933
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6022632
- OpenAlex
- W2805257646
- Cited by
- 1,918
- References
- 179
- Citations by year
- 2026: 245 · 2025: 298 · 2024: 298 · 2023: 328 · 2022: 300 · 2021: 228 · 2020: 130 · 2019: 65 · 2018: 21
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Funders
- AXA Research Fund
- ‘Fondation pour la Recherche sur Alzheimer’, Paris, France. Ce travail a bénéficié d'une aide de l’Etat ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- Canadian Institutes of Health Research
- National Research Council
- Alzheimer Society of Canada
- Rotary Club Livorno ‘Mascagni’/The Rotary Foundation (GG1758249)
- ADC (AG013854)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic system, cholinergic hypothesis, cholinesterase inhibitors, acetylcholine, cholinergic denervation, neurofibrillary degeneration, amyloid plaques, cognitive decline, cholinergic drugs, combination therapy
- MeSH terms
- Alzheimer Disease, Cholinesterase Inhibitors, Cognition, Cognition Disorders, Humans, Amyloid beta-Peptides, Neurofibrillary Tangles, Cholinergic Agents, Cholinergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.